Opna Bio Announces Fast Track Designation Granted to OPN-6602 for the Treatment of Multiple Myeloma

OPN-6602 Currently Treating Patients in Phase 1 Clinical Trial SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 15, 2026-- Opna Bio, a clinical-s ...
Seeking Alpha

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

WALTHAM, Mass., April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other ...
The Manila Times

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with ...
Seeking Alpha

Adicet Bio gains on FDA fast track designation for ADI-001 in lupus nephritis

Adicet Bio (NASDAQ:ACET) on Wednesday said that the U.S. Food and Drug Administration has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or ...
Nasdaq

Cabaletta Bio Receives FDA Fast Track Designation for CABA-201

PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies ...
Times Argus

A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for solid tumors, today announced that the U.S. Food and Drug Administration ...
Business Wire

Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to ...
The Caledonian-Record

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the ...